Crestview

Amblyopia, a common cause of reduced vision in one eye among children and young adults, affects between 1% and 5% of this population. It is often linked to conditions like uncorrected anisometropia and strabismus, which can also cause issues with focusing, eye coordination, depth perception, and contrast sensitivity. This research focuses on patients receiving Luminopia, an FDA-approved device treatment that uses therapeutic software to stimulate vision and manage amblyopia. This study observes patients who have been treated with Luminopia as part of their regular care without altering their treatment. Luminopia therapy involves using a device designed to improve vision in the weaker eye through specialized software. The registry collects clinical data from patients treated with Luminopia for at least 12 weeks, providing real-world insights into how the treatment is used by eye care professionals. Participants will be followed over several months with visits at 3, 6, 12, and 24 months to assess changes in visual acuity and stereoacuity, treatment duration, follow-up visits, and adherence to therapy. The study also measures how well improvements last after stopping treatment. Data is gathered through regular clinical assessments to help understand the effectiveness and durability of Luminopia treatment in everyday practice.